MODALIS THERAPEUTICS CORP has a total of 15 patent applications. Its first patent ever was published in 2019. It filed its patents most often in WIPO (World Intellectual Property Organization), Australia and Canada. Its main competitors in its focus markets biotechnology and pharmaceuticals are SHANGHAI CP GUOJIAN PHARMACEUTICAL CO LTD, SHENZHEN NONGKE GROUP CO LTD and ALGENTECH SAS.
# | Country | Total Patents | |
---|---|---|---|
#1 | WIPO (World Intellectual Property Organization) | 4 | |
#2 | Australia | 2 | |
#3 | Canada | 2 | |
#4 | Israel | 2 | |
#5 | Singapore | 2 | |
#6 | Brazil | 1 | |
#7 | EPO (European Patent Office) | 1 | |
#8 | Republic of Korea | 1 |
# | Industry | |
---|---|---|
#1 | Biotechnology | |
#2 | Pharmaceuticals |
# | Technology | |
---|---|---|
#1 | Microorganisms | |
#2 | Peptides | |
#3 | Therapeutic chemical compounds |
# | Name | Total Patents |
---|---|---|
#1 | Qin Yuanbo | 12 |
#2 | Yamagata Tetsuya | 11 |
#3 | Tetsuya Yamagata | 1 |
#4 | Yuanbo Qin | 1 |
Publication | Filing date | Title |
---|---|---|
WO2021033635A1 | Method for treating muscular dystrophy by targeting lama1 gene | |
WO2020085441A1 | Modified cas9 protein, and use thereof | |
SG11202100776SA | Novel transcription activator | |
SG11202012228QA | MODIFIED Cas9 PROTEIN AND USE THEREOF |